查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425167

电池超冷储存市场－2024年至2029年预测

Cell Cryopreservation Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计细胞低温储存市场在预测期内将以 22.35% 的复合年增长率成长。

冷冻保存是一种透过将细胞、组织和其他生物结构暴露在极低的温度下来来保存它们的技术。冷冻保存的应用包括细胞和器官保存、冷冻手术、生物化学和分子生物学中的应用、对食品科学的贡献、生态学和植物生理学的相关性、输血、骨髓移植、人工授精和体外受精（它涵盖了多种领域）领域，包括众多医疗应用，例如 IVF）。

冷冻保存对于储存用于器官移植的人类白血球抗原分型的细胞、促进不同医疗中心之间细胞和组织的安全运输以及研究未知传染病和病原体非常有价值。它具有多种优势，包括作为自然资源的作用。特别是，胚胎冷冻保存用于不孕症治疗的首次应用是在 20 世纪 90 年代末，当时一名被诊断患有乳癌的女性在接受化疗之前接受了自然体外受精。

市场驱动因素

  • 透过策略伙伴关係和联盟崛起

在全球范围内，战略合作伙伴关係和联盟在细胞冷冻保存市场的成长和开拓中发挥着至关重要的作用。这些联盟使公司能够利用互补的优势和资源，促进互惠互利，并提供在竞争形势中实现通用目标的策略路径。例如，2022 年 1 月，生命科学产业温控供应链解决方案的全球领导者 Cryoport, Inc. 宣布与 Cell Matters, SA 建立策略合作伙伴关係。此合作关係旨在为白血球衍生疗法提供端到端冷冻保存服务，并支持自体和同种异体细胞疗法。该合作伙伴关係还包括共同开拓销售这些服务的商业性方法。与 Cell Matters 的这种策略关係不仅加强了 Cryoport Systems 的咨询服务，而且有助于持续创新和开发适合市场需求的温控包装解决方案。这些合作伙伴关係和有针对性的收购符合生命科学产业不断变化的需求，并加强了 Cryoport 的全面供应链解决方案。

此外，2023 年 6 月，专门从事细胞疗法和病毒载体的全方位服务受託製造厂商(CDMO) SCTbio 将加入专门从事细胞疗法和再生医学先进解决方案的公司 Cyto-care。与.eu GmbH 合作。该合作伙伴关係的重点是提高欧洲细胞疗法开发的冷冻保存品质。其目的是满足白血球材料高效采集、冷冻保存、品管和物流能力的关键需求，以支持细胞治疗工作流程的各个方面。此次合作强调了该行业对推进冷冻保存技术并将细胞治疗无缝整合到医疗保健中的承诺。

  • 推动该领域的新科学发展

在快速发展的细胞冷冻保存领域，持续的科学发展正在越来越频繁地改变这一现状。冷冻保存的潜在应用是巨大的，并且不断扩大。目前该领域的研究特别关注整个器官的长期保存和持续活力，代表了医学进步的重要前沿。目前，心臟、肝臟和胰臟等器官只能在体外存活数小时。冷冻保存有可能将这一关键时限显着延长几天甚至更长。这些突破性技术有可能彻底改变器官移植手术、减少物流挑战并挽救更多生命。

这些进步的一个主要方面是新型冷冻保护剂的开发。它是保护细胞在冷冻和解冻过程中免受损​​伤的重要物质。另一个重要的发展是玻璃化，这是一种快速冷冻细胞的技术，使它们处于玻璃状状态而不是形成结晶。这种创新方法可望减少冻融过程中的细胞损伤。认识到解冻细胞与冷冻一样有害，人们正在开发新的解冻方法。

总之，细胞冷冻保存的动态形势是一项科学突破，它释放了器官保存的新可能性，提高了冷冻保护剂的有效性，改进了方法，完善了细胞解冻的微妙过程，其特点是不断发展。总的来说，这些进步有助于冷冻保存技术的持续发展，对医学和医疗保健实践产生深远的影响。

市场挑战

  • 与应用相关的高成本

由于冷冻保护剂、储存设施和专用设备的相关成本，细胞冷冻保存，特别是大规模应用，带来了巨大的财务挑战。采购关键冷冻保护剂对于在冷冻过程中保护细胞至关重要，其成本构成了整体支出。具有受控环境的先进储存设施进一步推高了成本。

精确冷冻和解冻过程所需的专用设备也是细胞冷冻保存的财务考量。为了应对这些挑战，人工智慧 (AI) 的整合正在成为一种变革性的解决方案。人工智慧的好处包括增强安全措施和优化生物材料的储存条件，为低温保存实践提供具有成本效益的改进潜力。

依应用，细胞冷冻保存市场分为干细胞、卵母细胞及胚胎卵子、精子细胞、肝细胞等。

细胞低温储存市场策略性地细分为特定应用。干细胞（细胞冻存）可用于再生医学，卵子和胚胎细胞储存可用于辅助生殖技术，精子细胞冻存可用于不孕症治疗，肝细胞储存可用于促进药物研究。 「其他」类别强调了低温保存的多种用途。总而言之，这些部分强调了低温保存对再生医学、生殖医学和科学研究的不同贡献。

欧洲预计将占据细胞冷冻保存市场的巨大份额

预计欧洲将在细胞冷冻保存市场中发挥关键作用，该地区受到现代社会冷冻保存实践探索的影响。这项探索由 CRYOSOCIETIES主导，计划旨在探索冷冻对生命的时间性和基本概念的变革性影响。 「CRYOSOCIETIES」由四个计划组成，每个子项目都有助于透过人种学研究和理论框架全面了解「悬浮生命」的创造。第一个子计划重点在于德国的脐带血储存。第二个子计划将调查西班牙的卵子冷冻情况，探讨女性决定储存卵子的动机以及卵子冷冻保存在生殖诊所和更广泛的生殖部门中的作用。第三个子计划重点关注英国濒危和灭绝物种的低温保存，特别是冰冻方舟慈善机构和 CryoArks 生物库的工作。

为了补充这些实证研究，第四个子计划采用理论方法并检验「暂停生命」的意义。这项理论探讨旨在阐明与不同人体冷冻实践相关的时间和空间机制。总之，「CRYOSOCIETIES」计划对欧洲背景下的低温保存进行了多方面的检验，并强调了其多样化的应用，从再生治疗到未来的繁殖和濒危物种保护工作。

企业产品

  • 细胞低温保存溶液 (Irvine Scientific) - FUJIFILM Irvine Scientific 的细胞低温保存溶液是一种化学成分明确的无蛋白质配方，严格遵守 cGMP 标准。 PRIME-XV FreezIS 冷冻保存产品有利于多种细胞类型的冷冻保存，例如间质干细胞(MSC) 和人类 T 细胞。冷冻保存后，进行彻底的验证以评估细胞标记、活力和倍数扩增。 PRIME-XV FreezIS 冷冻保存解决方案采用温和的冷冻过程，可有效最大程度地减少冷衝击造成的潜在损害。
  • 细胞冷冻介质和盐基溶液 (Sartorius) - Sartorius 提供生物保存解决方案，包括使用细胞冷冻介质和盐基溶液进行短期冷冻保存和长期冷冻保存。 NutriFreez® 细胞冷冻、NutriStor® 专为保存细胞而定制，包括干细胞、T 细胞和 PBMC 等脆弱类型。这些解决方案确保在生物保存过程中提供无动物成分 (ACF) 条件，这对于在无异源和 ACF 系统中培养细胞时保持同质性非常重要。 NutriFreez(R) 和 NutriStor(R) 已经证明了经过验证的可靠性和坚定不移的一致性，即使在低温储存、冷冻和解冻等过程中也表现出卓越的性能和恢復率。
  • 细胞株冷冻保存 (Sigma-Aldrich) - 达姆施塔特 Merck KGaA 专门从事细胞株冷冻保存并具有多种优势。这些包括降低微生物污染的风险、降低与其他细胞株交叉污染的可能性，以及降低遗传漂变和型态变化的风险。工作总是使用经过传代编号的细胞进行。这种方法不仅提高了整体效率，还降低了成本，包括消耗品和员工时间。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章细胞深冷保存市场：副产品

  • 介绍
  • 细胞冷冻介质
  • 装置
  • 消耗品

第六章 电池超低温保存市场：依应用分类

  • 介绍
  • 干细胞
  • 卵子和胚胎细胞
  • 精子细胞
  • 肝细胞
  • 其他的

第七章细胞低温保存市场：依最终用途

  • 介绍
  • 生物製药和製药公司
  • 研究机构
  • 生物样本库
  • 试管婴儿诊所
  • 其他的

第八章细胞低温保存市场：依地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Irvine Scientific
  • Biogenuix
  • Cryo-Cell
  • Sartorius
  • Sigma-Aldrich
  • Cytiva
  • AMSBIO
  • Cocoon Hospital
  • Charles River Laboratories
  • Transgen Biotech
简介目录
Product Code: KSI061616271

The cell cryopreservation market is estimated to grow at a CAGR of 22.35% during the forecast period.

Cryopreservation is a technique that involves preserving organelles, cells, tissues, or other biological structures by subjecting them to extremely low temperatures. The applications of cryopreservation span various areas, including- preserving cells or organs; cryosurgery; applications in biochemistry and molecular biology; contributions to food sciences; relevance in ecology and plant physiology; and numerous medical applications, such as blood transfusion, bone marrow transplantation, artificial insemination, and in vitro fertilization (IVF).

Cryopreservation offers several advantages, including the ability to bank cells for human leukocyte antigen typing for organ transplantation, facilitating the safe transport of cells and tissues across different medical centers, and serving as a valuable resource for research into unknown transmissible diseases or pathogens. Notably, the first instance of embryo cryopreservation for fertility preservation occurred in the late 1990s, involving the application of a natural IVF cycle before chemotherapy in a woman diagnosed with breast cancer.

Market Drivers

  • Rise due to strategic partnerships and collaborations

Globally, strategic partnerships and collaborations play a pivotal role in driving growth and development in the cell cryopreservation market. These alliances allow companies to capitalize on complementary strengths and resources, fostering mutual benefits and providing a strategic pathway for achieving shared objectives amid a competitive landscape. For instance, in January 2022, Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced a strategic partnership with Cell Matters, S.A. This collaboration aims to deliver end-to-end cryopreservation services for leukapheresis-derived therapies, supporting both autologous and allogeneic cell therapies. The partnership includes the joint development of a commercial approach for marketing these services. This strategic relationship with Cell Matters not only enhances Cryoport Systems' consulting services but also contributes to ongoing innovation and the development of temperature-controlled packaging solutions tailored to market needs. These alliances and targeted acquisitions are strengthening Cryoport's comprehensive supply chain solutions, aligning with the evolving needs of the life sciences industry.

Further in June 2023, SCTbio, a full-service contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors, collaborated with Cyto-care.eu GmbH, a company specializing in advanced solutions for cell therapy and regenerative medicine. The collaboration is focused on enhancing the quality of cryopreservation for cell therapy development in Europe. The goal is to address the critical need for efficient collection, cryopreservation, quality control, and logistics capabilities of leukapheresis materials, supporting various aspects of the cell therapy workflow. This partnership underscores the industry's commitment to advancing cryopreservation techniques and ensuring the seamless integration of cell therapies into the healthcare landscape.

  • New Scientific developments driving the field

In the rapidly advancing field of cell cryopreservation, ongoing scientific developments are reshaping the landscape with increasing frequency. The potential applications of cryopreservation are vast and continually expanding. Current research in this realm is particularly focused on the preservation of whole organs for extended storage and sustained viability, presenting a significant frontier in medical advancement. As it stands, organs like the heart, liver, and pancreas can endure only a few hours outside the body. Cryopreservation holds the promise of substantially extending this critical timeframe to several days or even longer. Such breakthroughs could revolutionize organ transplantation procedures, mitigating logistical challenges and potentially saving more lives.

A key facet of these advancements lies in the development of new cryoprotectants-substances crucial for shielding cells from damage during the freezing and thawing process. Another pivotal development involves vitrification, a technique that freezes cells so rapidly that they assume a glass-like state rather than forming ice crystals. This innovative approach holds promise in reducing cell damage during freezing and thawing. Recognizing that thawing cells can be as detrimental as freezing them, novel thawing methods are also under development.

In essence, the dynamic landscape of cell cryopreservation is marked by the continuous development of scientific breakthroughs, unlocking new possibilities for organ preservation, improving cryoprotectant efficacy, enhancing methods, and refining the delicate process of thawing cells. These advancements collectively contribute to the ongoing evolution of cryopreservation technologies with profound implications for medical science and healthcare practices.

Market Challenges

  • High cost associated with the application

Cryopreserving cells, especially in large-scale applications, pose significant financial challenges due to expenses associated with cryoprotectants, storage facilities, and specialized equipment. The procurement costs of crucial cryoprotectants, essential for safeguarding cells during freezing, contribute to the overall expenditure. Advanced storage facilities with controlled environments add further to the costs.

Specialized equipment required for precise freezing and thawing processes also factors into the financial considerations of cell cryopreservation. To address these challenges, the integration of artificial intelligence (AI) emerges as a transformative solution. AI's benefits include enhancing safety measures and optimizing the storage conditions of biological materials, presenting a potential for cost-effective improvements in cryopreservation practices.

By application, the cell cryopreservation market is segmented into stem cells, oocytes and embryotic cells, sperm cells, hepatocytes, and others

The cell cryopreservation market is strategically segmented, into specific applications. Stem cell cryopreservation holds promise for regenerative medicine, oocytes, and embryotic cell preservation supports assisted reproductive technologies, sperm cell cryopreservation aids fertility preservation, and Hepatocyte preservation facilitates drug research. The "others" category underscores cryopreservation's versatile applications. Altogether, these segments highlight cryopreservation's diverse contributions to regenerative medicine, reproductive health, and scientific research.

Europe is anticipated to hold a significant share of the Cell Cryopreservation Market

Europe is anticipated to play a significant role in the cell cryopreservation market, with the region being influenced by an exploration of cryopreservation practices within contemporary societies. This exploration is led by "CRYOSOCIETIES", a project delving into the transformative impact of cryopreservation on temporalities and the fundamental concept of life. "CRYOSOCIETIES" is structured into four subprojects, each contributing to a comprehensive understanding of the creation of "suspended life" through ethnographic studies and theoretical frameworks. The first subproject focuses on the storage of cord blood in Germany. The second subproject investigates the freezing of oocytes in Spain, exploring the motivations behind women's decisions to preserve their eggs and the role of oocyte cryopreservation within reproductive clinics and the broader reproductive sector. The third subproject concentrates on the cryopreservation of endangered or extinct species in the UK, particularly the initiatives of the Frozen Ark charity and the CryoArks biobank.

Complementing these empirical studies, the fourth subproject takes a theoretical approach, examining the implications of "suspended life." This theoretical exploration seeks to unravel the temporal and spatial regimes associated with various cryopreservation practices. In essence, the "CRYOSOCIETIES" project offers a multifaceted examination of cryopreservation within European contexts, shedding light on its diverse applications-from regenerative therapies to reproductive futures and conservation efforts for endangered species.

Market Developments

  • May 2022- OrganaBio, LLC, inaugurated a cutting-edge laboratory facility in Irvine, California, marking an expansion of its presence and capabilities from the southeast to the west coast. This new establishment is poised to provide comprehensive support services to clinical trial sponsors and Contract Research Organizations (CROs). The services encompass patient sample processing, analytical testing, cryopreservation, and storage. Leveraging OrganaBio's advanced techniques in cell isolation, characterization, and cryopreservation, the Irvine facility will replicate its success in collecting and processing patients' samples. The facility will incorporate state-of-the-art storage systems to ensure optimal preservation and long-term storage of samples.
  • December 2021- AMSBIO inaugurated a new office in Alkmaar, Netherlands, with the establishment of AMSBIO Europe BV. This strategic move is geared towards providing European customers swift and convenient access to the company's extensive range of high-quality products and consumables. Recognizing the significance of the European market, AMSBIO has long been planning measures to ensure that EU researchers can seamlessly receive next-day delivery of products without customs delays, import tariffs, or the need for additional documentation. The newly established AMSBIO Europe BV office is designed to streamline operations and maintain local stock, allowing EU customers to order and receive the company's market-leading life science products efficiently and at reduced costs.
  • October 2022- FUJIFILM Irvine Scientific, Inc., a prominent global player in the realm of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, unveiled a noteworthy development. The company announced that its PRIME-XV Stem FreezIS DMSO-Free cryopreservation medium has been selected as an excipient for an FDA-authorized clinical trial led by Vitro Biopharma. In this clinical trial, spearheaded by Vitro Biopharma, the primary objective is to explore both the safety and efficacy of intravenous infusions of their stem cell therapy product. The utilization of FUJIFILM Irvine Scientific's cryopreservation medium in this trial underscores the critical role it plays in maintaining the integrity and viability of stem cells, contributing to the success of advanced therapies and their potential applications in medical treatments.

Company Products

  • Cell Cryopreservation Solutions (Irvine Scientific)- FUJIFILM Irvine Scientific's cell cryopreservation solutions are meticulously crafted as chemically defined and protein-free formulations, produced in strict adherence to cGMP standards. PRIME-XV FreezIS cryopreservation products facilitate the freezing of diverse cell types, such as human mesenchymal stem cells (MSCs) and human T cells. Following cryogenic preservation, thorough validation is conducted, assessing cell markers, viability, and fold expansion. The PRIME-XV FreezIS cryopreservation solutions employ a gradual freezing process, effectively minimizing potential damage arising from cold shock.
  • Cell Freezing Media and Salt-Based Solutions(Sartorius)- Sartorius presents biopreservation solutions encompassing both short-term cold storage and extended cryopreservation with its Cell Freezing Media and Salt-Based Solutions. Tailored for the preservation of cells, including delicate varieties like stem cells, T cells, and PBMCs, NutriFreez® cell freezing, and NutriStor®. These solutions ensure the provision of animal component-free (ACF) conditions during biopreservation, crucial for maintaining uniformity when cultivating cells in xeno-free and ACF systems. Demonstrating established reliability and steadfast consistency, NutriFreez® and NutriStor® exhibit a notable performance and recovery rate following processes such as cold storage, freezing, and thawing.
  • Cryopreservation Of Cell Lines (Sigma-Aldrich) - Merck KGaA, Darmstadt, specializes in the cryopreservation of cell lines, offering several advantages. These include a diminished risk of microbial contamination, a lowered likelihood of cross-contamination with other cell lines, and a reduced risk of genetic drift and morphological changes. The work is performed using cells at a consistently maintained passage number. This approach not only enhances overall efficiency but also contributes to reduced costs, encompassing consumables and staff time.

Market Segmentation

By Product

  • Cell Freezing Media
  • Equipment
  • Consumables

By Application

  • Stem Cells
  • Oocytes And Embryotic Cells
  • Sperm Cells
  • Hepatocytes
  • Others

By End Use

  • Biopharmaceutical & Pharmaceutical Companies
  • Research Institutes
  • Biobanks
  • Ivf Clinics
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. CELL CRYOPRESERVATION MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Cell Freezing Media
  • 5.3. Equipment
  • 5.4. Consumables

6. CELL CRYOPRESERVATION MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Stem Cells
  • 6.3. Oocytes and Embryotic Cells
  • 6.4. Sperm Cells
  • 6.5. Hepatocytes
  • 6.6. Others

7. CELL CRYOPRESERVATION MARKET BY END-USE

  • 7.1. Introduction
  • 7.2. Biopharmaceutical & Pharmaceutical Companies
  • 7.3. Research Institutes
  • 7.4. Biobanks
  • 7.5. IVF Clinics
  • 7.6. Others

8. CELL CRYOPRESERVATION MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Irvine Scientific
  • 10.2. Biogenuix
  • 10.3. Cryo-Cell
  • 10.4. Sartorius
  • 10.5. Sigma-Aldrich
  • 10.6. Cytiva
  • 10.7. AMSBIO
  • 10.8. Cocoon Hospital
  • 10.9. Charles River Laboratories
  • 10.10. Transgen Biotech